文献速递自身免疫性与大疱性皮肤病药疹与重症皮肤不良反应

环孢素治疗表皮坏死松解症的新证据

New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis.
PubMed 文献 · J Invest Dermatol · 2017-01-01

该文评论一项系统综述及Gonzales-Herrada等的研究,指出在专科对症支持治疗基础上,环孢素可能降低表皮坏死松解症(从Stevens-Johnson综合征到中毒性表皮坏死松解症)的死亡风险。

要点

  • 环孢素可能降低表皮坏死松解症的死亡风险
  • 证据来自一项系统综述及Gonzales-Herrada等的研究
  • 专科对症支持治疗仍是基础,环孢素为其附加治疗

核心结论

  • 环孢素在降低表皮坏死松解症死亡风险方面可能有效

主要发现

  • 近期发表的系统综述与Gonzales-Herrada等的研究均强烈提示环孢素可降低死亡风险

临床怎么用

  • 在专科机构中,除必要的对症治疗外,可考虑将环孢素用于表皮坏死松解症的治疗

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sixty years after its original description by Sir Alan Lyell, epidermal necrolysis (from Stevens-Johnson syndrome to toxic epidermal necrolysis) seems finally amenable to a specific treatment in addition to essential symptomatic measures in specialized settings. A recently published systematic review and an article by Gonzales-Herrada et al. strongly suggest that cyclosporine is effective in reducing the risk of death.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Roujeau JC, Mockenhaupt M, Guillaume JC, et al. New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis. J Invest Dermatol. 2017. PMID: 28941473. doi:10.1016/j.jid.2017.07.828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。